Investment Rating - The report maintains a "Buy" rating for the company, reflecting optimism about its strategic development and the ongoing support from its major shareholder, China National Pharmaceutical Group [2][14]. Core Insights - The company has shown significant recovery in its business operations, with a 2023 revenue of 1.742 billion yuan, representing a year-over-year increase of 15.27%. The net profit attributable to shareholders reached 524 million yuan, up 34.60% year-over-year [2][10]. - Research and development investments have increased, with 163 million yuan allocated in 2023, marking an 18.73% growth. The company has also secured 52 patents and 34 medical device registrations during the reporting period [2][10]. - The company has entered the chemiluminescence sector, a recognized high-quality segment in in vitro diagnostics (IVD), with the approval of its fully automated chemiluminescence immunoassay analyzers [2][10]. - The partnership with China National Pharmaceutical Group is expected to enhance the company's internal growth channels and facilitate mergers and acquisitions, thereby boosting its market presence [2][10]. Financial Performance Summary - In Q4 2023, the company reported a revenue of 508 million yuan, a 30.69% increase year-over-year, and a net profit of 152 million yuan, up 27.22% year-over-year [2][10]. - The projected net profits for 2024 and 2025 have been adjusted to 630 million yuan and 763 million yuan, respectively, reflecting a decrease of 6.4% and 8.5% from previous forecasts [2][10]. - The company’s earnings per share (EPS) for 2023 is reported at 0.89 yuan, with projections of 1.07 yuan for 2024 and 1.30 yuan for 2025 [11]. Valuation Metrics - The current price-to-earnings (P/E) ratio is 22, with future projections of 18 for 2024, 15 for 2025, and 12 for 2026 [11][12]. - The company’s return on equity (ROE) is expected to improve from 14.06% in 2023 to 16.40% by 2026 [11]. Strategic Developments - The company has made strategic investments, including acquiring a stake in Longjin Biological Technology Co., which is aimed at further developing its platform capabilities [3]. - The signing of a product distribution agreement with ELITech Group Inc. is anticipated to reduce sales and promotion costs while enhancing brand recognition and expanding overseas market reach [2][10].

Product Development and Innovation - The company launched several new antibody reagents for immunohistochemistry, including CA 125, MSH6, and Galectin-3, marking their first introduction during the reporting period[1]. - The new antibody reagents are designed to provide diagnostic assistance to physicians based on routine staining methods[1]. - The company has received 510(k) exemptions for all newly launched antibody reagents, indicating compliance with regulatory standards[1]. - The focus on long-term development for these products suggests a strategic commitment to enhancing diagnostic capabilities in the healthcare sector[1]. - The introduction of these products is expected to expand the company's market presence and enhance its competitive edge in the biotechnology field[1]. - The company is actively collaborating with Fuzhou Maixin Biotechnology Development Co., Ltd. for the development of these new products[1]. - The antibody reagents cover a wide range of applications, indicating a comprehensive approach to immunohistochemistry diagnostics[1]. - The company aims to leverage these new products to drive future revenue growth and market expansion[1]. - The ongoing development of innovative diagnostic tools aligns with the company's strategic vision for long-term sustainability and growth[1]. - The successful launch of these products may lead to increased market share and improved financial performance in the upcoming fiscal periods[1]. - The company has launched 47 medical device registration certificates for new products, including mid-speed and ultra-high-speed automated chemiluminescence analyzers[11]. - The company has developed over 20 reference methods in its reference laboratory, focusing on enzymology, metabolites, proteins, and hormones[8]. - The company is focused on developing high clinical value testing reagents and aims to achieve full coverage of laboratory testing projects[58]. - The company is actively involved in the development of new products, including the vWFAg and anti-Xa reagent kits, which are currently in collaborative research projects with universities[123]. - The company has initiated a national key research and development project focused on the clinical application value of urine PSA for prostate hyperplasia, which started in April 2023[123]. Market Performance and Financials - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB in 2023, representing a year-on-year growth of 15%[114]. - The net profit margin increased to 30.07% in 2023, up from 25.76% in 2022[25]. - The overseas sales revenue grew by 7.87% year-on-year, reflecting the company's expanded international market influence[22]. - The production volume of in vitro diagnostic reagents increased by 25.25% year-on-year, reflecting strong market demand[33]. - The company reported a revenue increase of 15% year-over-year, reaching CNY 1.2 billion in 2023[170]. - New product launches contributed to 30% of total revenue, with three major products introduced in Q3 2023[170]. - Market expansion efforts led to a 40% increase in international sales, now accounting for 15% of total revenue[170]. - The company provided a forward guidance of 10% revenue growth for the next fiscal year, projecting revenues of CNY 1.32 billion[170]. Research and Development - The company's R&D investment for 2023 was ¥162,898,782.94, an increase of 18.73% compared to 2022[13]. - The company's R&D investment for 2023 amounted to ¥162,898,782.94, representing 9.35% of its operating revenue, an increase from 9.08% in 2022 and 7.94% in 2021[42]. - The R&D investment increased by 20%, amounting to CNY 200 million, focusing on innovative biotechnologies[170]. - The number of R&D personnel increased by 18.12% to 339 in 2023, with a notable rise in the number of bachelor's degree holders[40]. Strategic Partnerships and Collaborations - The company has established strategic partnerships with major firms such as Abbott, Roche, and Hitachi since 2013, enhancing its market position in the IVD sector[7]. - The company is actively collaborating with Fuzhou Maixin Biotechnology Development Co., Ltd. for the development of these new products[1]. - A new strategic partnership was established with a leading biotech firm to co-develop advanced therapies[170]. Governance and Compliance - The company has established a governance structure with a board of directors, supervisory board, and management team to ensure effective decision-making and oversight[106]. - The board of directors consists of 9 members, including 1 chairman and 1 vice chairman, overseeing major investment and strategic decisions[106]. - The supervisory board, composed of 3 members, is responsible for monitoring the actions of directors and management[106]. - The company has implemented a robust governance structure, ensuring compliance with legal requirements and enhancing operational efficiency[117]. - The internal control evaluation report indicates that 100% of the assets and operating income of the evaluated units are included in the consolidated financial statements[138]. - There were no significant defects identified in financial reporting or non-financial reporting during the evaluation period[138]. - The internal control measures established by the company include transaction authorization control, responsibility division control, and budget control, ensuring compliance in business operations[162]. - The company has not identified any significant deficiencies in its internal control during the reporting period[142]. Corporate Social Responsibility - The company has maintained a strong commitment to corporate social responsibility, being recognized as one of the "Top 500 Charitable Enterprises in China" in 2022[125]. - The company is committed to increasing its investment in charitable activities and giving back to society[153]. - The company emphasizes sustainable development, aiming to align short-term and long-term interests while enhancing its social contributions[156]. - The company aims to create more value for society through its charitable actions and contributions[153]. - The company has focused on employee welfare, providing competitive salaries and benefits, and ensuring a harmonious labor relationship[118]. - The company emphasizes environmental protection and sustainability, promoting energy-saving practices and raising awareness among employees[122]. Human Resources and Employee Management - The total number of employees at the end of the reporting period was 1,031, including 619 at the parent company and 412 at major subsidiaries[180]. - The company intends to optimize personnel selection and enhance employee training to build a highly skilled workforce for future growth[81]. - The company has established a performance management framework to enhance the performance evaluation and incentive mechanisms for senior management[189]. - The company has set up a compensation and assessment committee to oversee the performance evaluation of directors and senior management[189]. Financial Management and Investments - The company reported a net cash flow from investing activities increased by 71.14%, primarily due to the recovery of a large certificate of deposit from Mai Xin[61]. - The company has a total of ¥12,407,332.05 in bank deposits as of December 31, 2023, which are frozen as guarantee deposits[47]. - The company reported an investment amount of 5,500,000.00 CNY for the reporting period, a decrease of 95.98% compared to the previous year's investment of 136,775,000.00 CNY[67]. - The company has proposed a share repurchase plan, detailing the purpose, conditions, and funding sources[194]. - The total pre-tax remuneration for the board of directors and senior management amounted to CNY 1,019.18 million[192]. - The chairman, Zou Zuo Jun, received a pre-tax remuneration of CNY 243.44 million, while Liu Xi, a non-independent director, received CNY 201.78 million[192]. Future Outlook and Strategic Goals - The company aims to solidify its leading position in niche markets while accelerating transformation to build an international, comprehensive medical technology platform[57]. - The company plans to enhance market share by analyzing market conditions and policies, and by implementing a collaborative sales strategy of "instruments + reagents"[59]. - The company will adopt a dual approach of internal growth and external mergers and acquisitions to explore high-demand market areas and enhance its product portfolio[78]. - The management team emphasized a commitment to sustainability, targeting a 30% reduction in operational carbon footprint by 2025[170].

2023 年度独立董事述职报告 北京九强生物技术股份有限公司 2023 年度独立董事述职报告 各位股东及股东代表： 2023 年度独立董事述职报告 作为北京九强生物技术股份有限公司（以下简称"公司"）的独立董事，报告期 内本人任职期间严格按照《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司独立董事管理办法》《上市公司自律监管指引第 2 号——创业板上市公司规范 运作》等法律、法规以及《北京九强生物技术股份有限公司章程》（以下简称"《公 司章程》"）和《北京九强生物技术股份有限公司独立董事工作制度》（以下简称"《独 立董事工作制度》"）的相关规定和要求，本着客观、公正、独立的原则勤勉尽责、 独立履职，及时了解公司的生产经营及发展情况，促进公司规范运作、健康发展，维 护公司、全体股东特别是中小股东的利益。现将 2023 年度工作情况报告如下： 一、公司独立董事基本情况 叶军，1967 年 5 月出生，中国籍，无境外永久居留权，本科。1990 年 7 月毕业 于西安电子科技大学；1990 年 8 月-1992 年 6 月供职于电子部六所，任助理工程师； 1992 年 7 月-1994 年 4 月供职于电 ...

2023 年度监事会工作报告 北京九强生物技术股份有限公司 2023 年度监事会工作报告 2023 年，北京九强生物技术股份有限公司（以下简称"公司"）监事会按照《公 司法》《证券法》和《公司章程》的规定，认真履行法律、法规赋予的各项职责，围 绕公司年度生产经营目标切实开展各项工作。公司全体监事恪尽职守、勤勉尽责、努 力工作，保障了公司规范运作和资产及财务的准确完整，维护了公司权益及股东权益。 现将 2023 年监事会工作报告如下： 一、2023 年度公司监事会工作情况 报告期内，共召开 9 次监事会。监事会成员列席了公司 2023 年度历次股东大会 和董事会会议，认真审阅了会议的每一项议案和决议，同时对会议的审议程序进行了 监督，并对决议的贯彻执行进行了监督，全力保证公司治理规范运作。具体情况如下： | 会议届次 | 召开日期 | 会议决议刊登的指定网站 查询索引 | 内容 | 会议决议刊 登的信息披 | | --- | --- | --- | --- | --- | | | | | | 露日期 | | | | | 一、审议通过《关于公司<2022 年度监 | | | | | | 事会工作报告>的议案》； ...

董事会提名委员会工作规则 第一章 总则 北京九强生物技术股份有限公司 第一条 为进一步建立健全北京九强生物技术股份有限公司（以下简称"公 司"）董事、高级管理人员的选择标准和程序，完善公司治理结构，根据《中华 人民共和国公司法》及《北京九强生物技术股份有限公司章程》（以下简称"《公 司章程》"）及其他有关法律、行政法规、部门规章和其他规范性文件规定，公司 特设立董事会提名委员会，并制定本规则。 第二条 提名委员会是董事会按照《公司章程》设立的专门工作机构。 第二章 人员组成 第三条 提名委员会由三名董事组成，其中独立董事应占多数。 第四条 提名委员会委员由董事长、二分之一以上独立董事或者三分之一 以上董事提名，并由董事会选举产生。 第五条 提名委员会设召集人一名，在委员内选举产生，并报请董事会批 准。召集人由独立董事委员担任，负责主持提名委员会工作。 第六条 提名委员会委员任期与董事任期一致，委员任期届满，连选可以 连任。期间如有委员不再担任公司董事职务或应当具有独立董事身份的委员不再 具备《公司章程》所规定的独立性，自动失去委员资格，并由董事会根据本规则 第三至第五条规定补足委员人数。 董事任期届满未及时改 ...

董事会关于独立董事独立性情况的专项意见 北京九强生物技术股份有限公司 经核查独立董事陈永宏先生、杨建平先生、叶军先生的任职经历以及签署的《独 立董事独立性自查情况表》，上述人员未在公司担任除独立董事以外的任何职务，也 未在公司主要股东公司担任任何职务，与公司以及主要股东之间不存在利害关系或其 他可能妨碍其进行独立客观判断的关系，因此，公司独立董事符合《上市公司独立董 事管理办法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规 范运作》中对独立董事独立性的相关要求。 北京九强生物技术股份有限公司董事会 2024 年 3 月 29 日 董事会关于独立董事独立性情况的专项意见 根据证监会《上市公司独立董事管理办法》《深圳证券交易所股票上市规则》 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等要 求，北京九强生物技术股份有限公司（以下简称"公司"）董事会，就公司在任独立 董事陈永宏先生、杨建平先生、叶军先生的独立性情况进行评估并出具如下专项意见： ...

北京九强生物技术股份有限公司 Beijing Strong Biotechnologies, Inc. 章 程 二零二四年三月 1 | 目录 | | --- | | 第一章 | 总则 | 3 | | --- | --- | --- | | 第二章 | 经营宗旨和范围 | 4 | | 第三章 | 股份 | 4 | | | 第一节 股份发行 4 | | | | 第二节 股份增减和回购 5 | | | | 第三节 股份转让 7 | | | 第四章 | 股东和股东大会 | 7 | | | 第一节 股东 8 | | | | 第二节 股东大会的一般规定 10 | | | | 第三节 股东大会的召集 14 | | | | 第四节 股东大会的提案与通知 16 | | | | 第五节 股东大会的召开 17 | | | | 第六节 股东大会的表决和决议 21 | | | 第五章 | 董事会 | 25 | | | 第一节 董事 25 | | | | 第二节 董事会 29 | | | 第六章 | 总经理及其他高级管理人员 | 35 | | 第七章 | 监事会 | 37 | | | 第一节 监事 37 | | | | 第二节 监事会 ...

关于北京九强生物技术股份有限公司 2023 年度募集资金存放与使用情况的专项核查意见 中国国际金融股份有限公司（以下简称"中金公司"或"保荐机构"）作为北京九 强生物技术股份有限公司（以下简称"九强生物"或"公司"）2022 年可转换公司债券 的持续督导机构，根据《证券发行上市保荐业务管理办法》《上市公司监管指引第 2 号 ——上市公司募集资金管理和使用的监管要求》《深圳证券交易所创业板股票上市规则》 等相关规定履行持续督导职责，现就九强生物可转换公司债券募集资金截至 2023 年 12 月 31 日止的存放与使用情况进行了专项核查，核查意见如下： 一、2022 年可转换公司债券募集资金基本情况 （一）实际募集资金金额、资金到位时间 中国国际金融股份有限公司 1、公司募集资金使用情况 （1）公司可转换公司债券募集资金按照募集资金使用计划实施，募集资金使用情 况如下： 单位：人民币元 | 项目 | | | | | | 金额 | | --- | --- | --- | --- | --- | --- | --- | | 募集资金净额 | | | | | | 1,126,854,744.28 | | 减：置换预先投 ...

关于对北京九强生物技术股份有限公司 控股股东及其他关联方占用资金情况 的专项审计说明 立信中联会计师事务所(特殊普通合伙) LixinZhonglian CPAs (SPECIAL GENERAL PARTNERSHIP) "。" " " " " 此码用于证明该审计报告是否由具有执业许可的会计师事务所出 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http:// 投告编码.j.gov.cn）"进行在线 目 录 关于对北京九强生物技术股份有限公司控股股东及其他关联方占用资金 情况的专项审计说明 1—2 北京九强生物技术股份有限公司2023年度非经营性资金占用及其他关联资 金往来情况汇总表 1 新(# t 用: Property 中联会计师事务所(特殊普通合伙) inZhonglian CPAs (SPECIAL GENERAL PARTNERSHIP) 关于对北京九强生物技术股份有限公司 控股股东及其他关联方占用资金情况 立信中联专审字[2024]D-0106号 的专项审计说明 立信中联专审字[2024]D-0106号 北京九强生物技术股份有限公司全体股东; 我们接受委托,审计了北京九强生物技术股 ...

重大信息内部报告制度 北京九强生物技术股份有限公司 重大信息内部报告制度 第一章 总则 第一条 为规范北京九强生物技术股份有限公司(以下简称"公司")的重大信息 内部报告工作，保证公司内部重大信息的快速传递、归集和有效管理，及时、准确、 全面、完整地披露信息，维护投资者的合法权益，根据《中华人民共和国公司法》、 《中华人民共和国证券法》、《上市公司信息披露管理办法》、《深圳证券交易所创业板 股票上市规则》、《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公 司规范运作》等法律、规章及公司章程的要求，结合本公司的实际情况，制定本制度。 第二条 本制度所称重大信息是指对公司股票及其衍生品种的交易价格或者投 资决策可能或者已经产生较大影响的尚未公开的信息。 第三条 本制度所称报告义务人包括公司控股股东、持有公司 5%以上股份的股 东、公司董事、监事、高级管理人员、各部门负责人、各控股子公司负责人、公司派 驻参股子公司的董事、监事和高级管理人员以及公司各部门中重大事件的知情人等。 第四条 本制度适用于公司、全资子公司、控股子公司及参股公司。 第二章 一般规定 第五条 公司董事会是公司重大信息的管理机构。 ...